Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by K. Fairley
A1-2: Cost-Effectiveness of Interleukin 28B Genotype-Guided Protease Inhibitor Therapy in Treatment-Naive Patients With Hepatitis C Virus Genotype 2 or 3
Clinical Medicine and Research
Medicine
Home Care
Community
Related publications
A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Impact of Interleukin-28b Gene Polymorphism [Rs12979860] on Egyptian Patients Infected With Hepatitis C Virus Genotype-4
Eastern Mediterranean Health Journal
Medicine
The Cost-Effectiveness of Hepatitis C Treatments in Treatment Naïve Genotype 1 Patients
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections
Gastroenterology
Hepatology
Gastroenterology
Cost-Effectiveness of Telaprevir in Genotype 1 Chronic Hepatitis-C Virus Infection in Venezuela
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness of Cyp2c19*2 Genotype Guided Selection of Clopidogrel or Ticagrelor in Hong Kong Chinese Patients With Acute Coronary Syndrome
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
A Randomized, Controlled Study of Peginterferon Lambda-1a/Ribavirin ± Daclatasvir for Hepatitis C Virus Genotype 2 or 3
SpringerPlus
Multidisciplinary
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy
Gastroenterology
Hepatology
Gastroenterology
Efficacy of Boceprevir, an NS3 Protease Inhibitor, in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naive Patients With Genotype 1 Hepatitis C Infection (SPRINT-1): An Open-Label, Randomised, Multicentre Phase 2 Trial
The Lancet
Medicine
